Octapharma conveys update on development plan for SubQ-8 at ISTH 2019
Category: #health  By Pankaj Singh  Date: 2019-07-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Octapharma conveys update on development plan for SubQ-8 at ISTH 2019

Octapharma has reportedly presented an update on the clinical development and pre-clinical data of SubQ-8 in a conference at the International Society on Thrombosis and Haemostasis Congress 2019. SubQ-8 integrates a human cell line-derived recombinant FVIII simoctocog alfa with a recombinant VWF fragment dimer from a human cell line, in a unique approach to enable uptake of subcutaneous FVIII into the circulation.

Larisa Belyanskaya, Head of Haematology International Business Unit at Octapharma, stated that the organization is thrilled to share the update and future plans for the clinical development of the drug with the haemophilia community at the ISTH Congress. The organization believes that subcutaneous administration of FVIII could be critical in helping patients to receive a ‘state of the art’ treatment for haemophilia A and that it is pleased with the favorable preclinical data with SubQ-8 and its response among the haemophilia community, she added.

Olaf Walter, Octapharma’s Board Member, was quoted saying that Octapharma is dedicated to the enhancement of lives of the people with coagulation disorders and the company is proud to be creating a product with so much potential to meet a major need for patients with haemophilia A.

Walter further added that the ISTH Congress accords with the registration of the first patient in phase 1/2 clinical study of SubQ-8 in formerly treated patients suffering from haemophilia A, which is a major breakthrough in the clinical development of this drug.

According to credible sources, the scientific symposium considered how SubQ-8 could possibly address the longstanding needs of individuals with haemophilia A. Consistent intravenous supply of FVIII poses a substantial burden to patients with haemophilia A and their families. Alternate routes of administration may assist in reducing this burden and enhance adherence to prophylaxis.

The first candidate is about to be registered in a phase 1/2 study to evaluate safety and pharmacokinetics of the product in formerly treated patients with haemophilia A, and the outcomes of this study will decide the right dosing of SubQ-8 in forthcoming phase 3 studies among adults and children, reported sources.

Source Credit
https://www.octapharma.com/en/about/newsroom/press-releases/news-single-view.html?tx_ttnews%5Btt_news%5D=1119&cHash=8ca83e60edb343cccef107d2ba006579

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...